Search Patents
  • Patent number: 5177190
    Abstract: A method is disclosed for isolating and purifying C5a receptor from human polymorphonuclear leukocytes. C5a is a complement-derived protein which is important as a mediator of inflammatory responses. C5a receptor may be used to screen create and quantify C5a antagonists useful as anti-inflammatory agents and immunoregulants and to generate monoclonal and polyclonal anti-C5a receptor antibodies useful as anti-inflammatory agents and immunoregulants.
    Type: Grant
    Filed: January 22, 1992
    Date of Patent: January 5, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Thomas E. Rollins, Martin S. Springer
  • Patent number: 5451521
    Abstract: This invention relates to recombinant Factor VIII:c variants, methods to produce the variants and pharmaceutical compositions containing same. The variants of this invention are characterized by modification of one or more specific proteolytic cleavage sites encompassing the arginine residues at positions 226, 336, 562, 740, 776, 1313, 1648, or 1721. The variants possess similar procoagulant activity to that of human Factor VIII:c.
    Type: Grant
    Filed: December 9, 1986
    Date of Patent: September 19, 1995
    Assignee: Genetics Institute, Inc.
    Inventors: Randal J. Kaufman, Debra D. Pittman, John J. Toole, Jr.
  • Patent number: 5358932
    Abstract: Human protein C molecules are modified to provide increased resistance to inactivation by human plasma factors while retaining substantially the biological activity of human protein C. The modifications are generally to the heavy chain of protein C, which chain may be substituted with a protein C heavy chain of non-human origin, such as bovine, yielding a chimeric protein C molecule. The human protein C heavy chain may also be modified to be human-like, in that at least one amino acid from a non-human sequence may be substituted for the corresponding residue(s) of the human sequence, thereby allowing the molecule to retain substantially human characteristics yet having increased resistance to inactivation. Also included are methods for producing the modified protein C molecules and pharmaceutical compositions thereof.
    Type: Grant
    Filed: September 23, 1993
    Date of Patent: October 25, 1994
    Assignee: ZymoGenetics, Inc.
    Inventors: Donald C. Foster, Richard D. Holly
  • Patent number: 5200510
    Abstract: Methods for purifying factor VIII:C, von Willebrand factor (vWF) or complexes thereof from heterogeneous biological fluids are disclosed. The methods utilize a binding peptide, specific to either factor VIII:C or vWF, bound to an insoluble matrix. Peptides suitable for use within the methods are also disclosed.
    Type: Grant
    Filed: March 2, 1988
    Date of Patent: April 6, 1993
    Assignee: ZymoGenetics, Inc.
    Inventors: Anur A. Kumar, Frederick S. Hagen, Andrzej Z. Sledziewski
  • Patent number: 5728553
    Abstract: A process for the preparation of albumin which has extremely low levels of or is essentially free of colorants, metal ions, human proteins, fragments of albumin, polymers or aggregates of albumin, and viruses, and which is relatively non-glycated, relatively high in free thiol and with an intact C-terminus. The process comprises passing albumin (preferably expressed and secreted by transformed yeast) through two chromatography purifications, ultrafiltering the product, passing through two further chromatography steps and again ultrafiltering the product.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: March 17, 1998
    Assignee: Delta Biotechnology Limited
    Inventors: Andrew R. Goodey, Darrell Sleep, Hendrik van Urk, Stephen Berezenko, John R. Woodrow, Richard A. Johnson, Patricia C. Wood, Steven J. Burton, Alan V. Quirk, David St. J. Coghlan, Mark J. Wilson
  • Patent number: 5700659
    Abstract: A highly thermostable polypeptide possessing protein disulfide isomerase (PDI) activity, a gene coding for the polypeptide and a process for producing the polyeptide are provided. The polypeptide possessing PDI activity is characterized by A) having a capability of catalyzing a disulfide exchange in proteins, B) recognizing mainly ribonuclease A as a substrate, C) having a suitable active temperature of 20.degree. to 70.degree. C., D) being stable at a pH value of 6 to 9, and E) having a molecular weight of about 60,000 to 62,000. Since it has a higher thermostability and exhibits a stable activity in a wider dithiothreitol concentration range as compared with the conventional PDI, it is possible to provide a novel enzyme active protein which can be advantageously used for a refolding reaction of certain proteins.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 23, 1997
    Assignee: Kabushiki Kaisha Toyota Chuo Kenkusho
    Inventors: Yukio Yamada, Osamu Asami, Hidehiko Sugiyama, Chie Idekoba, Fumihiko Hoshino, Masana Hirai, Tsutomu Kajino, Takao Imaeda, Kiyoko Sarai
  • Patent number: 6150328
    Abstract: Purified BMP-2 and BMP-4 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.
    Type: Grant
    Filed: June 14, 1991
    Date of Patent: November 21, 2000
    Assignee: Genetics Institute, Inc.
    Inventors: Elizabeth A. Wang, John M. Wozney, Vicki A. Rosen
  • Patent number: 4977246
    Abstract: Disclosed is a method of recovery of antihemophilic factor (AHF) from human plasma by precipitation with citric acid, sodium citrate, or potassium citrate.
    Type: Grant
    Filed: June 6, 1989
    Date of Patent: December 11, 1990
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: Ted C. K. Lee, Michael E. Hrinda
  • Patent number: 5691171
    Abstract: A method for the production of indigo and indirubin dyes using a recombinant Escherichia coli containing a gene encoding a phenol hydroxylase from Bacillus stearothermophilus. The dyes are used for coloring cloth and the like.
    Type: Grant
    Filed: October 23, 1995
    Date of Patent: November 25, 1997
    Assignee: Board of Trustees operating Michigan State University
    Inventors: Patrick J. Oriel, In Cheol Kim
  • Patent number: 5109114
    Abstract: A purified protein, factor J, which has inhibitory properties which prevent the formation or the dissociation of C1 complex and a method of purification for said protein. The method including the following sequential chromatography steps: anion exchange, QAE-Sephadex, heparin-Sepharose affinity, Mono-Q and hydroxylapatite.
    Type: Grant
    Filed: September 12, 1989
    Date of Patent: April 28, 1992
    Assignee: Beth Israel Hospital
    Inventor: Anne Nicholson-Weller
  • Patent number: 5453490
    Abstract: A method for the production of commercial quantities of highly purified interleukin-1 inhibitor (IL-1i) from a recombinant host is disclosed. A preferred recombinant E. coli host for use in this method is also disclosed.
    Type: Grant
    Filed: August 30, 1994
    Date of Patent: September 26, 1995
    Assignee: Synergen, Inc.
    Inventors: Robert Hageman, Stephen P. Eisenberg, David Dripps, Ronald Evans, Henryk Cudny, Robert C. Thompson
  • Patent number: 5273744
    Abstract: This invention relates to the development of a vaccine against Theileria parva, which is a protozoan parasite infecting cattle in Africa. The invention specifically relates to the use of the 67 kDa glycoprotein from the surface of the T. parva sporozoite as an immunogen for inducing immunoprotection against T. parva in bovine species. This 67 kDa antigen is produced using recombinant genetics. Plasmids containing nucleic acid segments encoding the antigen, host cells containing the nucleic acid segments and recombinant methods for producing the antigen are part of this invention.
    Type: Grant
    Filed: February 11, 1992
    Date of Patent: December 28, 1993
    Assignee: International Laboratory for Research on Animal Diseases
    Inventors: Anthony J. Musoke, Vish Nene, Keith Iams, Vinand M. Nantulya
  • Patent number: 5225537
    Abstract: Methods are disclosed for producing hybrid phospholipid-binding proteins from eukaryotic cells. DNA constructs comprising a transcriptional promoter, at least one signal sequence and a hybrid phospholipid-binding protein coding sequence comprising at least one lipocortin lipid-binding domain joined to a gla-domainless, vitamin K-dependent protein and a transcriptional terminator are also disclosed.
    Type: Grant
    Filed: December 29, 1989
    Date of Patent: July 6, 1993
    Assignee: ZymoGenetics, Inc.
    Inventor: Donald C. Foster
  • Patent number: 4894444
    Abstract: Immunologically intact protein or peptide immunogens are recovered from vaccines consisting of immunogen-aluminum hydroxide (alum) complexes. Recovery consists of dissolution of the complexes with an alkali metal salt of a carboxylic acid at a basic pH, reduction of the pH to physiological levels, removal of excess dissolvent and isolation of the protein or peptide immunogen.
    Type: Grant
    Filed: July 16, 1987
    Date of Patent: January 16, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Edgar M. Scattergood, Roy W. Grabner
  • Patent number: 5489519
    Abstract: A novel protein associated with multidrug resistance in living cells and capable of conferring multidrug resistance on a cell is disclosed and nucleic acids encoding the novel isoforms are disclosed. Transformant cell lines which express the nucleic acid encoding the novel protein are also disclosed. Further, diagnostic and treatment methods using the novel protein, nucleic acids and cell lines are also disclosed.
    Type: Grant
    Filed: October 26, 1993
    Date of Patent: February 6, 1996
    Assignee: Queen's University at Kingston
    Inventors: Roger G. Deeley, Susan P. C. Cole
  • Patent number: 5116953
    Abstract: An aqueous lactoferrin solution can be thermally treated for heat pasteurization or spray drying purposes substantially without impairing the iron-binding ability of the lactoferrin by first adjusting the ionic strength thereof in accordance with the formulae, wherein I is ionic strength and T is temperature (.degree.C.):log I.ltoreq.-T/10+5 (60.ltoreq.T.ltoreq.80.degree. C.)log I.ltoreq.-3 (T.gtoreq.80.degree. C.).
    Type: Grant
    Filed: October 17, 1989
    Date of Patent: May 26, 1992
    Assignee: Snow Brand Milk Products Co., Ltd.
    Inventors: Shunichi Dosako, Rika Shinooka, Maki Tanaka
  • Patent number: 5196516
    Abstract: The present invention is concerned with a pseudorabies virus (PRV) vaccine comprising a polypeptide of the PRV glycoprotein gII or a fragment thereof which was shown to be the site of interaction of PRV neutralizing antibodies. Vector vaccines capable to express a polynucleotide fragment coding for such a polypeptide also form part of the present invention.
    Type: Grant
    Filed: July 21, 1989
    Date of Patent: March 23, 1993
    Assignee: Akzo N.V.
    Inventors: Christa S. Schreurs, Thomas C. Mettenleiter, Artur J. Simon, Noemi Lukacs, Hanns J. Rziha
  • Patent number: 5449765
    Abstract: The present invention is concerned with a pseudorabies virus (PRV) vaccine comprising a polypeptide of the PRV glycoprotein gII or a fragment thereof which was shown to be the site of interaction of PRV neutralizing antibodies. Vector vaccines capable to express a polynucleotide fragment coding for such a polypeptide also form part of the present invention.
    Type: Grant
    Filed: October 31, 1994
    Date of Patent: September 12, 1995
    Assignee: Akzo N.V.
    Inventors: Christa S. Schreurs, Thomas C. Mettenleiter, Artur J. Simon, Noemi Lukacs, Hanns J. Rziha
  • Patent number: 5474933
    Abstract: The present invention provides the isolated genes encoding marine melA from the genus Shewanella, especially from the species S. colwelliana, and the melA encoded thereby in homogeneous form. Further, the invention provides antibodies to marine melA as well as methods of using the melA to induce oyster larval settlement. Moreover, these marine melA genes are also useful as selectable markers for genetic engineering.
    Type: Grant
    Filed: November 8, 1993
    Date of Patent: December 12, 1995
    Assignee: The University of Maryland
    Inventors: Ronald M. Weiner, William C. Fuqua, Jr.
  • Patent number: 5474922
    Abstract: The present invention relates to .beta.-1,4-galactanase derived from A. aculeatus which have (a) a pH-optimum between 3.0 and 5.0, (b) an isoelectric point of 2.5-3.5, (c) a molecular weight of between 30,000 and 50,000, and (d) a temperature optimum between 10.degree. and 50.degree. C.
    Type: Grant
    Filed: July 15, 1993
    Date of Patent: December 12, 1995
    Assignee: Novo Nordisk A/S
    Inventors: Kurt Dorreich, Henrik Dalboge, Jan M. Mikkelsen, Marcel Mischler, Flemming M. Christensen
Narrow Results

Filter by US Classification